Ultragenyx

Yahoo Finance • 2 days ago

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - RARE

NEW ORLEANS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ult... Full story

Yahoo Finance • 2 days ago

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)... Full story

Yahoo Finance • 3 days ago

Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory

We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on RARE. Ultragenyx Pharmaceutical Inc.'s share was trading at... Full story

Yahoo Finance • 4 days ago

Ultragenyx to Participate at Investor Conferences in March

NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic dise... Full story

Yahoo Finance • 7 days ago

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today repo... Full story

Yahoo Finance • 7 days ago

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm

Did you buy RARE common stock between August 3, 2023, and December 26, 2025? Affected Ultragenyx Pharmaceutical Inc.Investor Summary Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass... Full story

Yahoo Finance • 8 days ago

Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors

LOS ANGELES, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ultragenyx Pharmaceutical, Inc., (“Ultragenyx” or the "Company") (NASDAQ: RARE) investors of a class action on behalf of investors that bought securities between... Full story

Yahoo Finance • 10 days ago

CLASS ACTION ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ultragenyx and Mereo BioPharma and Encourages Investors to Contact the Firm

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Ultragenyx Pharmaceutical... Full story

Yahoo Finance • 10 days ago

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or... Full story

Yahoo Finance • 10 days ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact D... Full story

Yahoo Finance • 10 days ago

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

SAN DIEGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025, inclusive (the “C... Full story

Yahoo Finance • 11 days ago

Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) is one of the 17 biotechnology stocks with more than 50% upside. On February 3, the price target on Ultragenyx Pharmaceutical (NASDAQ:RARE) was set to $60 by H.C. Wainwright analyst Ram Selvaraju, w... Full story

Yahoo Finance • 11 days ago

Kessler Topaz Meltzer & Check, LLP - Class Action Announcement for Ultragenyx Pharmaceutical Inc. Investors: A Securities Fraud Class Action Lawsuit Was Filed Against Ultragenyx Pharmaceutical Inc.

Did you buy RARE common stock between August 3, 2023, and December 26, 2025? Affected Ultragenyx Pharmaceutical Inc.Investor Summary Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass... Full story

Yahoo Finance • 12 days ago

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

NEW YORK, Feb. 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August... Full story

Yahoo Finance • 14 days ago

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Feb. 13, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (NASDAQ... Full story

Yahoo Finance • 15 days ago

ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August... Full story

Yahoo Finance • 16 days ago

Class Action Announcement for Ultragenyx Pharmaceutical Inc. (RARE): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc.

Did you buy RARE common stock between August 3, 2023, and December 26, 2025? Affected Ultragenyx Pharmaceutical Inc.Investor Summary Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)What: Securities fraud class action lawsuit filedClass... Full story

Yahoo Finance • 18 days ago

RARE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Ultragenyx Pharmaceutical Inc. Class Action

SAN DIEGO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between... Full story

Yahoo Finance • 19 days ago

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August... Full story

Yahoo Finance • 21 days ago

Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is one of the 13 Best Revenue Growth Stocks to Buy Right Now. On January 30, Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE) resubmitted its Biologics License Application (BLA) to the U.S. Food and... Full story